ReachMD CME

00:05:00

Winning the CKD-aP Battle: A United Physician-Nurse...

ReachMD CME ·

2026/08/17

CME credits: 1.00 Valid until: 17-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/winning-the-ckd-ap-battle-a-united-physician-nurse-front/61000/ Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for

en

00:06:00

What You Don’t See: A Patient’s View of Living with...

ReachMD CME ·

2026/08/17

CME credits: 1.00 Valid until: 17-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/what-you-dont-see-a-patients-view-of-living-with-ckd-ap/60999/ Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for

en

00:07:30

Frontline Champions: Nurses as Drivers of...

ReachMD CME ·

2026/08/17

CME credits: 1.00Valid until: 17-08-2027 Claim your CME credit at https://reachmd.com/programs/cme/frontline-champions-nurses-as-drivers-of-symptom-based-ckd-ap-care/54094/ Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical

en

00:17:31

Rewriting the Calcium Code in ADH1

ReachMD CME ·

2026/07/31

CME credits: 0.25 Valid until: 31-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/rewriting-the-calcium-code-in-adh1/54833/ In this expert discussion, Drs. Michael Levine and Aliya Khan review emerging evidence in autosomal dominant hypocalcemia type 1 (ADH1), including findings from the CALIBRATE trial presented at ENDO 2026. They discuss how CaSR-targeted therapy with encaleret may address the underlying disease mechanism and highlight key efficacy and safety findings,

en

00:05:00

The Survival Ceiling in ES-SCLC: Why Checkpoint...

ReachMD CME ·

2026/07/27

CME credits: 0.50 Valid until: 27-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-survival-ceiling-in-es-sclc-why-checkpoint-blockade-alone-is-not-enough/60948/ This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies,

en

00:05:30

Clinical Evidence on Emerging Antigen-Directed...

ReachMD CME ·

2026/07/27

CME credits: 0.50 Valid until: 27-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-on-emerging-antigen-directed-strategies-in-es-sclc/60950/ This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies, including

en

00:05:45

On the Horizon: Emerging Antigen-Directed Strategies...

ReachMD CME ·

2026/07/27

CME credits: 0.50 Valid until: 27-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/on-the-horizon-emerging-antigen-directed-strategies-across-disease-stage/60951/ This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies,

en

00:04:30

Rationale of Emerging Antigen-Directed Strategies in...

ReachMD CME ·

2026/07/27

CME credits: 0.50 Valid until: 27-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/rationale-of-emerging-antigen-directed-strategies-in-frontline-es-sclc/60949/ This online educational activity examines next-generation therapeutic approaches for small cell lung cancer (SCLC) beyond traditional checkpoint inhibition. The program reviews the biologic rationale for targeting antigens such as fucosyl-GM1, DLL3, and B7-H3, highlighting diverse immune effector strategies,

en

01:05:30

Advancing Acromegaly Care: Diving Deeper Into...

ReachMD CME ·

2026/07/24

CME credits: 1.50 Valid until: 24-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/advancing-acromegaly-care-diving-deeper-into-diagnosis-guideline-application-and-emerging-therapiesa-fireside-chat-with-expert-perspectives/56307/ This program is a replay of the live symposium held at ENDO 2026. This program reviews challenges in diagnosis and management of acromegaly, with an emphasis on earlier recognition and informed clinical decision-making. Faculty discuss

en

00:04:15

The Case for Change: Why Perioperative Immunotherapy...

ReachMD CME ·

2026/07/23

CME credits: 0.50 Valid until: 23-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-case-for-change-why-perioperative-immunotherapy-matters-in-la-hnscc/60852/ This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging

en

00:07:30

Building the Team: Integrating Immunotherapy Into...

ReachMD CME ·

2026/07/23

CME credits: 0.50 Valid until: 23-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/building-the-team-integrating-immunotherapy-into-multidisciplinary-care/60854/ This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging

en

00:05:15

From Data to Decision: Patient Selection and...

ReachMD CME ·

2026/07/23

CME credits: 0.50 Valid until: 23-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-data-to-decision-patient-selection-and-real-world-application/60855/ This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging evidence

en

00:05:00

The Evidence Base: Key Trials and Emerging Data

ReachMD CME ·

2026/07/23

CME credits: 0.50 Valid until: 23-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-evidence-base-key-trials-and-emerging-data/60853/ This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging evidence from key clinical

en

00:16:30

From Abstract to Action in Breast Cancer:...

ReachMD CME ·

2026/07/22

CME credits: 0.50 Valid until: 23-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-abstract-to-action-in-breast-cancer-interpreting-recent-data-on-oral-serds-and-endocrine-targeting-strategies/57230/ Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with

en

00:43:15

Clear Skin, Clear Path: Transforming Psoriasis Care...

ReachMD CME ·

2026/07/20

CME credits: 1.00 Valid until: 20-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/clear-skin-clear-path-transforming-psoriasis-care-with-durable-biologic-and-oral-il-23-innovations/49227/ Psoriasis management often begins with topical therapies, phototherapy, or established biologics before escalation. This Broadcast Replay examines earlier biologic use and the role of oral IL-23 receptor antagonists, reviewing the efficacy and safety data, as well as practical

en

00:13:15

No Patient With CKD Left Behind: New Horizons in...

ReachMD CME ·

2026/07/14

CME credits: 0.25Valid until: 14-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/no-patient-with-ckd-left-behind-new-horizons-in-patients-with-ckd-regardless-of-diabetes-status/49260/ A growing body of evidence presented at ERA 2026 is reshaping the conversation around chronic kidney disease management, regardless of diabetes status. In this expert interview, Dr. Katherine Tuttle and Dr. Brendon Neuen examine emerging data on nonsteroidal mineralocorticoid receptor

en

00:16:00

Chairperson’s Perspective: Incorporating Novel...

ReachMD CME ·

2026/07/09

CME credits: 0.25 Valid until: 09-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-incorporating-novel-treatment-options-for-schizophrenia-into-clinical-practice-overcoming-clinical-inertia/54751/ Although dopamine D₂ receptor antagonists have long been the standard treatment for schizophrenia, many patients experience inadequate symptom control or adverse effects that affect adherence. Emerging evidence supports a role for muscarinic M₁/M₄ receptor

en

00:05:30

Applying CAS, EUGOGO, VISA: A Micro Case

ReachMD CME ·

2026/07/06

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/applying-cas-eugogo-visa-a-micro-case/60940/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. Discover how our

en

00:06:00

Beyond IGF-1R: IL-6R Inhibition and Future Sequencing

ReachMD CME ·

2026/07/06

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/beyond-igf-1r-il-6r-inhibition-and-future-sequencing/60946/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care

en

00:05:45

Designing Efficient Clinic Workflows for TED Therapy...

ReachMD CME ·

2026/07/06

CME credits: 1.00 Valid until: 06-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/designing-efficient-clinic-workflows-for-ted-therapy-access/60943/ Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care

en

All Episodes

Similar Podcasts

Ciência

RFI Português

天方烨谈

基因频道

Quilo de Ciencia - Cienciaes.com

Jorge Laborda

The Field Guides

The Field Guides

Down to Earth

FRANCE 24 English